These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 348088)

  • 1. ARA-C analogs.
    Alberto P
    Antibiot Chemother (1971); 1978; 23():88-98. PubMed ID: 348088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
    Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anhydro-ara-5-fluorocytidine (AAFC) in gastrointestinal cancer. A phase II study.
    Falkson G; Falkson HC; du Plessis HE; Meyer TE
    Cancer Clin Trials; 1980; 3(4):341-4. PubMed ID: 6159121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
    Nakamura T; Ueda T
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clincal pharmacology of O2,2'-cyclocytidine.
    Rodriguez DH; Loo TL; Bodey GP; Freireich EJ
    Clin Pharmacol Ther; 1975 Jan; 17(1):66-72. PubMed ID: 1173058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
    Kreis W; Gordon CS; DeJager R; Krakoff IH
    Cancer Res; 1975 Sep; 35(9):2453-60. PubMed ID: 1149046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative ultrastructure of submaxillary salivary glands from mice treated with cytosine arabinoside, cyclocytidine, and anhydro-ara-5-fluorocytidine.
    Liss RH; Charest MC; Mead JA
    Cancer Treat Rep; 1976 Jul; 60(7):881-8. PubMed ID: 64296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
    Kreis W; Woodcock TM; Gordon CS; Krakoff IH
    Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II clinical study of anhydro-ara-5-fluorocytosine (AAFC) and ICRF-159 combination in adenocarcinoma of digestive origin.
    Brugarolas A; Buesa JM; Lacave AJ; Gracia Marco M; Valle Pereda M
    Cancer Clin Trials; 1978; 1(4):289-95. PubMed ID: 93030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs.
    Ho DH; Carter CJ; Loo TL; Abbott RL; McBride CM
    Drug Metab Dispos; 1975; 3(4):309-13. PubMed ID: 240662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
    Rosowsky A; Kim SH; Ross J; Wick MM
    J Med Chem; 1982 Feb; 25(2):171-8. PubMed ID: 7057424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine and human leukemias.
    Burchenal JH
    Bibl Haematol; 1975; (40):665-77. PubMed ID: 1100047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activities of acyl derivatives of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosylcytosine in cell culture.
    Sato K; Nomura A; Moffatt JG
    Antimicrob Agents Chemother; 1977 Feb; 11(2):191-7. PubMed ID: 66909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
    Kataoka T; Sakurai Y
    Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
    Movassaghi N; Higgins G; Pyesmany A; Baehner R; Chard R; Sather H; Hammond D
    Med Pediatr Oncol; 1984; 12(5):352-6. PubMed ID: 6208468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.
    Alberto P; Rozencweig M; Gangji D; Brugarolas A; Cavalli F; Siegenthaler P; Hansen HH; Sylvester R
    Eur J Cancer (1965); 1978 Feb; 14(2):195-201. PubMed ID: 75105
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety.
    Turcotte JG; Srivastava SP; Steim JM; Calabresi P; Tibbetts LM; Chu MY
    Biochim Biophys Acta; 1980 Sep; 619(3):619-31. PubMed ID: 7459369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.